Wednesday, February 3, 2010

Five Short Answer Questions

Five SAQs

1. A patient passed 100mls of heavily bloodstained urine after suffering severe pelvic injury. How will you manage this problem?
--comment: in answering this question take note that the main clue is SEVERE pelvic injury. This patient is suffering from significant impact and also other injuries. The trauma care and resuscitation according to ATLS apply.

2. What is the lupus anticoagulant? What is its relevance to ICU practice?
----interesting question

3. Critically evaluate the role of percutaneous tracheostomy in the ICU.


A. Bedside percutaneous tracheostomy has now become an alternative to operative surgical tracheostomy:

-requires less time to perform

-less expensive

-typically performed sooner (OR doesn't have to be scheduled)

Complications may be less frequent with percutaneous tracheostomy than surgical tracheostomy. Results of a study of 46 patients (CCM 1991), when compared to ST: PT is performed in shorter time and significantly less haemorrhage, stomal infection, pneumothorax, all pre-decannulation adverse events, pre decannulation problems per procedure, tracheal stenosis and cosmetic deformity.

In a metaanalysis of 17 randomised, controlled trials (1212 patients), percutaneous tracheostomy decreased wound infections compared to both surgical tracheostomy done in the OR and ICU. (Critical Care 2006)

Percutaneous tracheostomy also decreased bleeding and mortality when compared to surgical tracheostomy performed in OR only.

The second metaanalysis showed perioperative complications (including death, serious cardiorespiratory events, and minor complications) were rare but more common with percutaneous tracheostomy. In contrast minor postoperative complications were more common among patients receiving surgical tracheostomy. (CCM 1999)

The different outcomes of the two meta analysis may reflect the different techniques used to perform PT.

-the first meta-analysis included only studies that used percutaneous dilational tracheostomy. In contrast the second meta-analysis included studies of PT performed using a variety of techniques.

-A recent RC study showed no difference in long term (median 20 m0nth) follow up.(CCM 2006)

-Disadvantages of PT include an increased risk of anterior tracheal injury and posterior tracheal wall perforation.

Taken together, the data suggest Percutaneous dilational tracheostomy offers numerous advantages compared to surgical tracheostomy.
The benifit of PT may be substantially less depending on the technique employed.

4. An audit of central venous catheters (CVC) in your ICU shows sepsis related rate of 30% . Outline what you will do?
----This is an audit question

5. Critically evaluate the use of plasma troponin in the critically ill patient.
---is a critically evaluate question
at the end of the debate must include ---in my opinion or in my practice....

Tuesday, February 2, 2010

arterial blood supply to the spinal cord


Liver Cirrhosis


Cirrhosis of the liver has a number of different causes:


1. Alcohol

The development of cirrhosis depends upon the amount and regularity of alcohol intake. Chronic, high levels of alcohol consumption injure liver cells. Thirty percent of individuals who drink daily at least eight to sixteen ounces of hard liquor or the equivalent for fifteen or more years will develop cirrhosis. Alcohol causes a range of liver diseases; from simple and uncomplicated fatty liver (steatosis), to the more serious fatty liver with inflammation (steatohepatitis or alcoholic hepatitis), to cirrhosis.


2. Nonalcoholic fatty liver disease (NAFLD)

NAFLD refers to a wide spectrum of liver diseases that, like alcoholic liver disease, ranges from simple steatosis, to nonalcoholic steatohepatitis (NASH), to cirrhosis. All stages of NAFLD have in common the accumulation of fat in liver cells. The term nonalcoholic is used because NAFLD occurs in individuals who do not consume excessive amounts of alcohol, yet, in many respects, the microscopic picture of NAFLD is similar to what can be seen in liver disease that is due to excessive alcohol. NAFLD is associated with a condition called insulin resistance, which, in turn, is associated with the metabolic syndrome and diabetes mellitus type 2. Obesity is the most important cause of insulin resistance, metabolic syndrome, and type 2 diabetes. NAFLD is the most common liver disease in the United States and is responsible for 24% of all liver disease. In fact, the number of livers that are transplanted for NAFLD-related cirrhosis is on the rise. Public health officials are worried that the current epidemic of obesity will dramatically increase the development of NAFLD and cirrhosis in the population.


3. Cryptogenic cirrhosis (cirrhosis due to unidentified causes)

is a common reason for liver transplantation. It is termed cryptogenic cirrhosis because for many years doctors have been unable to explain why a proportion of patients developed cirrhosis. Doctors now believe that cryptogenic cirrhosis is due to NASH (nonalcoholic steatohepatitis) caused by long standing obesity, type 2 diabetes, and insulin resistance. The fat in the liver of patients with NASH is believed to disappear with the onset of cirrhosis, and this has made it difficult for doctors to make the connection between NASH and cryptogenic cirrhosis for a long time. One important clue that NASH leads to cryptogenic cirrhosis is the finding of a high occurrence of NASH in the new livers of patients undergoing liver transplant for cryptogenic cirrhosis. Finally, a study from France suggests that patients with NASH have a similar risk of developing cirrhosis as patients with long standing infection with hepatitis C virus. (See discussion that follows.) However, the progression to cirrhosis from NASH is thought to be slow and the diagnosis of cirrhosis typically is made in patients in their sixties.


4. Chronic viral hepatitis

is a condition where hepatitis B or hepatitis C virus infects the liver for years. Most patients with viral hepatitis will not develop chronic hepatitis and cirrhosis. For example, the majority of patients infected with hepatitis A recover completely within weeks, without developing chronic infection. In contrast, some patients infected with hepatitis B virus and most patients infected with hepatitis C virus develop chronic hepatitis, which, in turn, causes progressive liver damage and leads to cirrhosis, and, sometimes, liver cancers.


5. Inherited (genetic) disorders

result in the accumulation of toxic substances in the liver which lead to tissue damage and cirrhosis. Examples include the abnormal accumulation of iron (hemochromatosis) or copper (Wilson's disease). In hemochromatosis, patients inherit a tendency to absorb an excessive amount of iron from food. Over time, iron accumulation in different organs throughout the body causes cirrhosis, arthritis, heart muscle damage leading to heart failure, and testicular dysfunction causing loss of sexual drive. Treatment is aimed at preventing damage to organs by removing iron from the body through bloodletting (removing blood). In Wilson disease, there is an inherited abnormality in one of the proteins that controls copper in the body. Over time, copper accumulates in the liver, eyes, and brain. Cirrhosis, tremor, psychiatric disturbances and other neurological difficulties occur if the condition is not treated early. Treatment is with oral medication that increases the amount of copper that is eliminated from the body in the urine.

6. Primary biliary cirrhosis (PBC)
is a liver disease caused by an abnormality of the immune system that is found predominantly in women. The abnormal immunity in PBC causes chronic inflammation and destruction of the small bile ducts within the liver. The bile ducts are passages within the liver through which bile travels to the intestine. Bile is a fluid produced by the liver that contains substances required for digestion and absorption of fat in the intestine, as well as other compounds that are waste products, such as the pigment bilirubin. (Bilirubin is produced by the breakdown of hemoglobin from old red blood cells.). Along with the gallbladder, the bile ducts make up the biliary tract. In PBC, the destruction of the small bile ducts blocks the normal flow of bile into the intestine. As the inflammation continues to destroy more of the bile ducts, it also spreads to destroy nearby liver cells. As the destruction of the hepatocytes proceeds, scar tissue (fibrosis) forms and spreads throughout the areas of destruction. The combined effects of progressive inflammation, scarring, and the toxic effects of accumulating waste products culminates in cirrhosis.


7. Primary sclerosing cholangitis (PSC)

is an uncommon disease found frequently in patients with ulcerative colitis . In PSC, the large bile ducts outside of the liver become inflamed, narrowed, and obstructed. Obstruction to the flow of bile leads to infections of the bile ducts and jaundice and eventually causes cirrhosis. In some patients, injury to the bile ducts (usually as a result of surgery) also can cause obstruction and cirrhosis of the liver.


8. Autoimmune hepatitis

is a liver disease caused by an abnormality of the immune system that is found more commonly in women. The abnormal immune activity in autoimmune hepatitis causes progressive inflammation and destruction of liver cells (hepatocytes), leading ultimately to cirrhosis.


9. Infants can be born without bile ducts (biliary atresia) and ultimately develop cirrhosis. Other infants are born lacking vital enzymes for controlling sugars that leads to the accumulation of sugars and cirrhosis. On rare occasions, the absence of a specific enzyme can cause cirrhosis and scarring of the lung (alpha 1 antitrypsin deficiency).


10. Less common causes of cirrhosis include unusual reactions to some drugs and prolonged exposure to toxins, as well as chronic heart failure (cardiac cirrhosis). In certain parts of the world (particularly Northern Africa), infection of the liver with a parasite (schistosomiasis) is the most common cause of liver disease and cirrhosis.

Spinal Cord Trauma



American Spinal Injury Association (ASIA) Grading Scale for Spinal Cord Injury

A = No motor or sensory function preserved
B = Sensory but no motor function preserved
C = Nonuseful motor function preserved (less than antigravity strength)
D = Motor function preserved but weak
E = Normal motor and sensory function

Neurology Injury:

1. Complete Spinal Cord Injury (SCI)
2. Incomplete SCI
3. Specific Incomplete SCI syndromes:
a. Central Cord Syndrome
b. Brown-Sequard syndrome
c. Anterior Cord Syndrome
d. Conus medullaris Syndrome
.
The Effects of Spinal Cord Injury.
The exact effects of a spinal cord injury vary according to the type and level injury, and can be organized into two types:

Complete SCI
There is no function below the level of the injury. Voluntary movement is impossible and physical sensation is impossible. Complete injuries are always bilateral, that is, both sides of the body are affected equally.

A person with an incomplete injury retains some sensation below the level of the injury. Incomplete injuries are variable, and a person with such an injury may be able to move one limb more than another, may be able to feel parts of the body that cannot be moved, or may have more functioning on one side of the body than the other. In addition to a loss of sensation and motor function below the point of injury, individuals with spinal cord injuries will often experience other changes.Bowel and bladder function is associated with the sacral region of the spine, so it is very common to experience dysfunction of the bowel and bladder. Sexual function is also associated with the sacral region, and is often affected. Injuries very high on the spinal cord (C-1, C-2) will often result in a loss of many involuntary functions, such as breathing, necessitating mechanical ventilators or phrenic nerve pacing. Other effects of spinal cord injury can include an inability to regulate heart rate (and therefore blood pressure), reduced control of body temperature, inability to sweat below the level of injury, and chronic pain and also incontinence. Physical therapy and orthopedic instruments (e.g., wheelchairs, standing frames) are often necessary, depending on the location of the injury.The Location of the InjuryKnowing the exact level of the injury on the spinal cord is important when predicting what parts of the body might be affected by paralysis and loss of function.Below is a list of typical effects of spinal cord injury by location (refer to the spinal cord map to the right). Please keep in mind that the prognosis of complete injuries are predictable, incomplete injuries are very variable and may differ form the descriptions below.Cervical injuriesCervical (neck) injuries usually result in full or partial tetraplegia. Depending on the exact location of the injury, one with a spinal cord injury at the cervical may retain some amount of function as detailed below, but are otherwise completely paralyzed.

C3 vertebrae and above: Typically lose diaphragm function and require a ventilator to breathe.
C4: May have some use of biceps and shoulders, but weaker.
C5: May retain the use of shoulders and biceps, but not of the wrists or hands.
C6: Generally retain some wrist control, but no hand function.
C7 and T1: Can usually straighten their arms but still may have dexterity problems with the hand and fingers. C7 is the level for functional independence. Thoracic injuriesInjuries at the thoracic level and below result in paraplegia. The hands, arms, head, and breathing are usually not affected.

T1 to T8 : Most often have control of the hands, but lack control of the abdominal muscles so control of the trunk is difficult or impossible. Effects are less severe the lower the injury.

T9 to T12 : Allows good trunk and abdominal muscle control, and sitting balance is very good. Lumbar and Sacral injuriesThe effect of injuries to the lumbar or sacral region of the spinal canal is decreased control of the legs and hips, and anus.
Central cord syndrome (picture 1)
is a form of incomplete spinal cord injury characterized by impairment in the arms and hands and, to a lesser extent, in the legs. This is also referred to as inverse paraplegia, because the hands and arms are paralyzed while the legs and lower extremities work correctly.Most often the damage is to the cervical or upper thoracic regions of the spinal cord, and characterized by weakness in the arms with relative sparing of the legs with variable sensory loss.This condition is associated with ischemia, hemorrhage, or necrosis involving the central portions of the spinal cord (the large nerve fibers that carry information directly from the cerebral cortex). Corticospinal fibers destined for the legs are spared due to their more external location in the spinal cord.This clinical pattern may emerge during recovery from spinal shock due to prolonged swelling around or near the vertebrae, causing pressures on the cord. The symptoms may be transient or permanent.
Anterior Cord Syndrome (picture 2)
is also an incomplete spinal cord injury. Below the injury, motor function, pain sensation, and temperature sensation is lost; touch, propioception (sense of position in space), and vibration sense remain intact. Posterior Cord Syndrome (not pictured) can also occur, but is very rare.
Brown-Sequard Syndrome (picture 3)
usually occurs when the spinal cord is hemisectioned or injured on the lateral side. On the ipsilateral side of the injury (same side), there is a loss of motor function, propioception, vibration, and deep touch. Contralaterally (opposite side of injury), there is a loss of pain, temperature, and light touch sensations.

Variceal Bleeding

-Variceal bleeding is the most common lethal complication of cirrhosis. Acute bleeding episodes carry 20% mortality at 6 weeks.
-Mortality related to haemorrhage, liver decompensation, aspiration, hepatic encephalopathy, HRS, septicaemia and alcohol withdrawal.
-Varices are present in 50% of patients with cirrhosis and 85% of Child-Pugh C patients.

-Portal Hypertension -----> Collateral circulation to decompress pressure, junctions of squamous and columnar mucosae (gastroesophageal, anal, peristomal) -----> Development of varices. Risks factors for rupture: 1. portosystemic pressure gradient > 10-12 mmHg ii. variceal size > 5mm iii. progressive hepatic dysfunction.

Treatment goal:
1. Resuscitation
-airway control in massive haemorhage and obtunded patients
-NG aspiration may be necessary
-hemodynamic with blood and blood products aim for stability (initial lab results)
-watch for hypocalcemia and thrombocytopenia in massive transfusion
-thiamine and monitor alcohol withdrawal

2. Diagnosis-upper endoscopy
Findings-fresh fibrin clot from varix, nipple like protrusion, red signs, varices with no other potential bleeding source.

3. Therapy

A. Pharmacology:
1. Octreotide (somatostatin analog) is the drug of choice. Started immediately with suspicion of variceal bleeding. Minimal side effects
IV 50mcg bolus, infusion 50mcg/hr
2. vasopressin -potent vasoconstrictor, reduces splanchnic BF and portal pressure. Adverse cardiac events (MI, hypertension) in ~ 30% of patients. Concurrent IV nitroglycerin for SBP ~100mmhg has been shown to reduce the systemic SE's.
3. Non selective B blockers, not in acute setting. For primary and secondary prevention of variceal bleeding.
4. Antibiotic prophylaxis- to prevent infection and rebleeding in all cirrhotic patients with variceal bleeding.
Norfloxacin 400mg bd
or Ceftriaxone 1g daily

B. Endoscopy
1. Band ligation- is the technique of choice to control bleeding. Active bleeding is controlled in 80%-90% of patients after one or two treatments.
-lower incidence of esophageal ulceration, stricture formation, perforation, bacrteraemia and respiratory failure compared to sclerotherapy.
2. Sclerotherapy - for gastric variceal bleeding and massive variceal bleeding

C. TIPS



Transjugular Intrahepatic Pportosystemic Stent (TIPS) shunt

- Iatrogenic fistula between radicals of the hepatic and portal veins, created by interventional radiologists using ultrasonographic and fluoroscopic guidance
- An expandable metal stent is left in place and portosystemic pressue gradient is reduced to less than 12 mmHg

Indications:

i. Bleeding continues despite combinations of pharmacologic and endoscopic therapies
ii. Bleeding recurs after two endoscopic attempts at prevention
iii. Bleeding has occurred from gastric varices or portal hypertensive gastropathy

- The technical success rate is > 90%, with near universal success rate in bleeding control. Overall mortality is similar to endoscopic therapy.
-S hunt insufficiency is 15-60% within 6 months.
- Postprocedure bleeding recurrence---> dopler US examination for determining shunt patency. Revision of shunt usually results in low mortality

Complications:

- 20-30% develop transient deterioration of LFTs
- Up to 25% may experience new or worsened hepatic encephalopathy

D. Baloon tamponade
-gastric and oesophageal balloon devices for direct tamponade of the bleeding varices
-Sengstaken-Blakemore, Minnesota and Linton-Nachlas balloons--> for severe and persistent bleeding.

E. Other measures:
- surgical shunts
-non shunting operations
-embolisation of the short gastric veins in gastric variceal bleeding and splenectomy in splenic vein thrombosis
.........................................................................................................................................................................
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

SOMATOSTATIN AND ITS ANALOGS

Somatostatin inhibits the release of vasodilator hormones, such as glucagon, indirectly causing splanchnic vasoconstriction and decreased portal inflow.

It has a short half-life and disappears within minutes of a bolus infusion; octreotide is a long-acting analog of Somatostatin.

Pharmacodynamics — Following a bolus injection of either somatostatin or octreotide, portal venous inflow, portal pressures, azygos flow, and intravariceal pressures decrease within seconds. Of these effects, the changes in portal pressures, as measured by wedged hepatic pressures, are most variable and the decrease in collateral flow (azygos flow) are most consistently observed.


One of the most detailed studies to evaluate the pharmacodynamics of octreotide included 68 patients with cirrhosis who were given octreotide by four different methods (gastroenterology 2001):
-An intravenous injection of (50 or 500 microg) or placebo
-A 50 microg bolus followed by continuous infusion of 50 or 250 microg per hour or placebo infusion
-Repeated 50 microg injections or placebo after an initial 50 microg bolus
-After a placebo bolus and continuous infusion of 50 microg per hour.


Octreotide caused a marked but transient decrease in portal pressure and azygos blood flow and an increase in mean arterial pressure. These effects lasted only five minutes even with the addition of continuous infusions. Repeated bolus injections had shorter, less marked effects while continuous infusion did not decrease portal pressure, suggesting that there was rapid desensitization.
These findings make it unclear why octreotide should be of any benefit in portal hypertension since its effect on portal pressure is short-lived. However, the potential benefits of octreotide (and somatostatin) in portal hypertension may extend beyond the measures noted above. Both inhibit the release of glucagon and other hormones that have an important role in mediating the normal increase in mesenteric blood flow that occurs postprandially.

Variceal hemorrhage is associated with an increase in intestinal blood flow, presumably mediated by pathways that are activated by the presence of blood, a high protein substance, in the gut. Octreotide can blunt this response for at least 48 hours . In addition, activation of somatostatin receptors may decrease the rebound increase in portal venous pressure that occurs when blood enters the gastrointestinal tract and during correction of hypovolemia.


Clinical trials

A number of clinical trials have compared somatostatin or octreotide to either vasopressin or placebo in the management of active bleeding. An initial placebo-controlled trial failed to demonstrate a benefit for somatostatin; however, over 80 percent of those treated with placebo spontaneously stopped bleeding which may have obscured a treatment benefit . Several subsequent studies have shown somatostatin to be significantly superior to placebo with respect to achievement of hemostasis and to prevention of early rebleeding .


Somatostatin versus vasopressin — Somatostatin is also superior to vasopressin and balloon tamponade due in part to the virtual absence of side effects. A meta-analysis of trials comparing somatostatin to vasopressin found two benefits with somatostatin [gastroenterology 1995]:
1. A higher relative risk (1.62, 95 percent CI 1.37 to 1.93) of achieving initial control of the bleeding; the absolute benefit was such that only three or four patients had to be treated with somatostatin for one to derive benefit over therapy with vasopressin.
2. A lower risk of adverse effects (0 versus 10 percent with vasopressin).


However, these beneficial effects on bleeding have not been shown to improve survival.

The Liver




The liver has anatomically separate lobes and eight functionally independent segments based on blood supply and natural anatomic separations. These segments are used for surgical classification because they allow for hepatic resection along segmental planes, thus preserving function and tissue integrity. The surgical classification system is called Couinad's classification.

The four major lobes of the liver are divided by fissures and include:
i. the right anatomical lobe (larger), which has two smaller lobes located at its posterior-inferior surface
ii. the left anatomical lobe
iii. the smaller, inferior lobes are referred to as the caudate lobe and
iv. quadrate lobe.
The major division of the liver (left and right lobes) is the falciform ligament .

The human liver is the largest gland/organ in the body and weighs approximately 1500-1600 gm in adults (~2% of total body mass). It is known for having a large functional reserve and is responsible for an extensive number of complex functions in humans including:

1. Blood reservoir / filter
2. Regulation of blood coagulation
3. Glucose regulation
4. Erythrocyte breakdown and bilirubin excretion
5. Intermediary metabolism regulation (bile production)
6. Protein synthesis (albumin, coagulation factors, etc.)
7. Host defense
8. Pharmacokinetics / Drug metabolism
9. Hormone metabolism


Functional and Microanatomy

Hepatic tissue is made of 50,000-100,000 discrete, hexagonally shaped anatomic units called lobules . Lobules contain plates of hepatocytes arranged cylindrically around a centrilobular vein .

The portal tracts (or “triads”) include 4-5 tracks surrounding each lobule that contain
- hepatic arterioles which carry oxygenated blood from hepatic artery,
- the portal venules which carry partially deoxygenated blood from the portal vein,
- bile caniliculi that join to form bile ducts.



The hepatic sinusoids / ducts act as capillaries between the central vein and portal tracts and contain endothelial cells and macrophages ( Kupffer cells ).
Kupffer cells are responsible for phagocytosis of calonic bacteria, endotoxins, cellular debris, viruses, proteins, and particulate matter, antigen processing, and the release of proteins, enzymes, cytokines, and chemical mediators.
The Space of Disse lies between the hepatic sinusoids and the hepatocytes.
Additionally, and extensive system of lymphatic ducts and nerves is located through hepatic tissue.

The functional cellular anatomy of the liver can be divided into three zones:

- Zone 1 – closest to blood vessels, well oxygenated, least susceptible to injury
- Zone 2 – adequately oxygenated
- Zone 3 – closest to centrilobular vessels, least oxygenated, most susceptible to injury



Blood Supply


Normal hepatic blood flow is ~1500 cc/min in adults (25-30% of total CO) and normal hepatic blood volume is ~450 cc. The liver has the unique ability to augment circulating blood volume by up to 300 cc during low volume states such as dehydration or hemorrhage. Additionally, it can also hold up to 1 L of blood at the expense of hepatic congestion. The blood supply is a dual system also known as a portal system. The two major vessels that provide blood to the liver are the hepatic artery and portal vein .

The hepatic artery arises from the celiac artery (from aorta) and comprises 25-30% of total blood flow to the liver. It supplies 45-50% of oxygen requirement and flow is dependant on metabolic demand (autoregulated). The normal saO2 of blood in the hepatic artery is 98%. The portal vein is formed at the anastamosis of the superior mesenteric and splenic veins and comprises 70-75% of total blood flow to the liver. It supplies 50-55% of oxygen requirement and the normal saO2 of portal venous blood is 85%. This blood is partially deoxygenated prior to entering the liver in the stomach, spleen, intestines, and pancreatic vessels. Normal hepatic venous pressure is 7-10 mmHg and flow is dependent on blood flow to the GI tract and spleen. The blood from these organs is laden with nutrients from GI tract.


The intrahepatic circulation of blood is as follows:

The hepatic artery and portal vein split into left and right branches ---> enter liver and diminish in size throughout the hepatic tissue ---> become terminal hepatic arterioles and portal venules ---> drain directly into hepatic sinusoids (see above) ---> terminal hepatic venules into a central vein ---> sublobular veins which get larger and ultimately form ---> three major hepatic veins (right, middle, and left) ---> inferior vena cava.

Duct System



The duct system or hepatobiliary system is composed of the following:
i. Bile ducts from hepatic lobules combine to form
ii. the left and right hepatic ducts which connect to form the hepatic duct which together with
iii. the cystic duct from the gallbladder form
iv. the common bile duct which then meets with
v. the pancreatic duct and empties into the duodenum of the small intestine under the control of the Sphincter of Oddi:

Contract: bile is blocked from entering the duodenum

Relax: allows bile to enter the duodenum










THE HEPATIC PORTAL SYSTEM




The Hepatic Portal System

Introduction:
Portal System begins in the capillaries of the digestive organs and ends in the portal vein. Consequently, portal blood contains substances absorbed by the stomach and intestines. Portal blood is passed through the hepatic lobules where nutrients and toxins are absorbed, excreted or converted. Restriction of outflow through the hepatic portal system can lead to portal hypertension.


The liver is unusual in that it has a double blood supply:

1. The right and left hepatic arteries carry oxygenated blood to the liver
2. The portal vein carries venous blood from the GI tract to the liver.

The venous blood from the GI tract drains into the superior and inferior mesenteric veins; these two vessels are then joined by the splenic vein just posterior to the neck of the pancreas to form the portal vein. This then splits to form the right and left branches, each supplying about half of the liver.On entering the liver, the blood drains into the hepatic sinusoids, where it is screened by specialised macrophages (Kupffer cells) to remove any pathogens that manage to get past the GI defences. The plasma is filtered through the endothelial lining of the sinusoids and bathes the hepatocytes; these cells contain vast numbers of enzymes capable of braking down and metabolising most of what has been absorbed.

The portal venous blood contains all of the products of digestion absorbed from the GI tract, so all useful and non-useful products are processed in the liver before being either released back into the hepatic veins which join the inferior vena cava just inferior to the diaphragm, or stored in the liver for later use.


The venous blood from the GI tract drains into the superior and inferior mesenteric veins; these two vessels are then joined by the splenic vein just posterior to the neck of the pancreas to form the portal vein.

This then splits to form the right and left branches, each supplying about half of the liver.On entering the liver, the blood drains into the hepatic sinusoids, where it is screened by specialised macrophages (Kupffer cells) to remove any pathogens that manage to get past the GI defences. The plasma is filtered through the endothelial lining of the sinusoids and bathes the hepatocytes; these cells contain vast numbers of enzymes capable of breaking down and metabolising most of what has been absorbed.

The portal venous blood contains all of the products of digestion absorbed from the GI tract, so all useful and non-useful products are processed in the liver before being either released back into the hepatic veins which join the inferior vena cava just inferior to the diaphragm, or stored in the liver for later use.

Chronic liver injury results in activation of stellate cells within the space of Disse. This leads to the deposition of collagen and in time histologic changes of cirrhosis.
Cirrhosis also results in endothelial dysfunction and increased in resistance to flow within the hepatic sinusoids.

Sinusoidal hypertension and endothelial dysfunction produce Portal hypertension.

Three cardinal features:

1. Increased resistance to mesenteric vascular flow
2. Activation of the renal-angiotensin-aldosterone system resulting in Na and water retention and increased intravascular volume.
3. Increased mesenteric blood flow as a consequence of a hyperdynamic circulation.


Portal hypertension is responsible for the 5 complications of chronic liver disease:

1. Gastrointestinal bleeding

2. Ascites

3. Portosystemic encephalopathy

4. Hepato renal syndrome

5. Pulmonary disease:
a. Hepatopulmonary syndrome
b. Portopulmonary hypertension

The consequences of portal hypertension are due to portal systemic anastomosis formed by the body as an attempt to bypass the obstructed liver circulation. These collateral vessels form along the falciform ligament, diaphragm, spleen, stomach and peritoneum. The collaterals find their way to the renal vein where blood drained from the digestive organs is let into the systemic circulation.

Monday, February 1, 2010

Oesophageal Tamponade Tube



Oesophageal Tamponade Tube

Oesophageal varices arise as a result of portal hypertension. Bleeding oesophageal varices are associated with significant risk of mortality. Definitive management includes endoscopic sclerotherapy/banding +/- octreotide or transjugular intrahepatic portosystemic shunt (TIPS).

Indication:

1. Bleeding oesophageal varices
2. Failure of sclerotherapy/banding +/- octreotide to control bleeding
3. Delay or lack of availability of endoscopic intervention

Sengstaken –Blakemore (Minnesota modification) 4 channel tube:
Gastric Balloon
Gastric aspiration lumen
Oesophageal balloon
Oesophageal aspiration lumen

Policy guideline

The decision to insert a tube is made with consultation with the duty consultant intensivist and the duty consultant gastroenterologist/ general surgeon
All patients are to be endotracheally intubated prior insertion of Sengstaken-Blakemore tube
All patients are to be managed in the ICU
Risk of rebleeding after balloon insertion is 50%, all patients should undergo subsequent endoscopy and sclerotherapy after tube is removed.

Procedure


Check tube before insertion
Inflate the gastric balloon with 300 ml air, check and record the pressure in the in inflated gastric balloon
Inflate the oesohageal balloon with air, check and record the pressure in the inflated oesophageal balloon
Deflate both balloons completely and lubricate the tube
Insert tube orally under direct vision, using a laryngoscope; pass the tube to the 50-cm mark.
Do not inflate gastric balloon until correct tube placement is confirmed with X-Ray
Aspirate gastric lumen
Inflate gastric balloon with 300 ml of air, check the pressure in the gastric balloon, this should not exceed the pre insertion pressure by > 5 mmHg if the tube is correctly placed in the stomach. Higher pressures may indicate incorrect oesophageal placement, if high pressures present deflate balloon and repeat insertion and check X-Ray
Pull back tube until resistance is felt when the inflated gastric balloon rests in gastric fundus and against the oesophageal gastric junction
Apply traction (0.5-1kg) to the tube, i.e. 500ml or 100ml bag of fluid by pulley and cord
Inflate oesophageal balloon to a pressure of 35-40 mmHg
Recheck the position of the tube with X-Ray
Place on free drainage oesophageal and gastric lumens, and aspirate hourly or prn. Record aspirate and drainage volumes hourly to assess haemorrhagic losses
Balloons should not be inflated for > 24 hours

Contraindications:

. Known oesophageal stricture

. Unidentified source of bleeding

. Unprotected airway

Complications.

. Cardiac arryythmias
· Acute upper airway obstruction
· Oesophageal necrosis / rupture
· Aspiration pneumonia


The Sengstaken-Blakemore tube permits tamponade of both the distal esophagus and the gastric fundus. An accessory nasogastric tube permits aspiration of secretions from above the esophageal balloon.